btourbier

The very exciting session “How to partner more efficiently with charities, patient groups and foundations” got its last panelist confirmed this week!

Scheduled at 9 am to kick-off day second, this session will discuss the pros and cons of partnerships with charities, patient groups, and foundations. Our panelists will discuss the successful models they had the opportunity to take part in, create, or manage, and their aftermaths.

Furthermore, we will go deeper by addressing the downsides of these partnerships: it is not always easy to attract the charities and foundations to invest in start-ups or research projects. Though charities and foundations have been increasingly supporting start-up companies, early-stage projects and project development leading start-ups, it is complicated for them to spot the right project, to find the right innovation and target the molecules that have potential,  how can TTOs and research institutes improve the dialog to set up more efficient collaborations?

Moderated by Thomas Dentzer, General manager of Luxembourg BioHealth Cluster, this session will feature panelists profiles as varied as they are completing each other :

–        Robin Rasor, CEO of the TTO spin-off, University of Michigan, USA

–        Olivier Arnaud, Director Research Europe, JDRF, France

–        Sohini Chowdhury, VP Research Partnerships, the Michael J Fox Foundation, USA

–        Jerôme Van Biervliet, Senior Development Manager, VIB, Belgium

 

We are already looking forward to listening to these heavy league speakers !

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us!

 

Pharmaceutical Tech the Global Leader in B2B services supports BioFIT!

 

In the realm of Pharmacy, where innovation is rapid :

Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space

&

BioFIT is the perfect place to find the perfect match

 

Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers.

Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics.

With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.

Steering Committee member and panelist Cécile Théard-Jallu,  partner at de Gaulle Fleurance et Associés, France, shared a few words on the importance of using the law as a tool to develop your projects :

The law as a crucial tool within the innovation framework, is a topic mentionned in some of BioFIT 2015 sessions.

 

First, the subject is thoroughly developed in the session “Shaping the future of Open-Innovation :  does the IP legal framework need remodeling ?” addressed by 4 high-level experts :

–        Moderator : Timo Minssen, Associate Professor, University of Copenhagen, DK

–        Philippe Borne, Regional Representative Strasbourg, INPI Alsace, FR

–        Gauthier Obrecht, Patents Biotech Manager, Boerhinger Ingelheim, DE

–        Sumitra Rajagopala, CEO of BioAstra Technologies, CA

 

Moreover, on December 2nd in the session “How to implement and perform scientific and technological Due Diligence?” scheduled at 2pm, alongside Diane Seimetz, Co-founder, BioPharma excellence, DE, Carl Jessop, Due Diligence Director, Astrazeneca, UK,  David Malek, VP Business Development, Biolinerx, Israel and Martin Cadman, Director Scientific Licensing, GlaxoSmithKline, Cécile Théard-Jallu will share her expertise on the topic from a legal point of view.

 

So, is the law a tool or a constraint ? Come share your opinion at Biofit2015!

 

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us!

From small to big organizations, as our confirmed exhibitors,

find the perfect exhibition package to highlight your visibility during BioFIT 2015!

 

Besides highlighting your visibility, the exhibition has many other advantages :

• Improving your company’s image, prestige and credibility,
• Getting identified as a key innovative actor in Life Sciences,
• Reassert your corporate focus on innovations
• Speeding up your business strategy,
• Getting additionnal networking opportunities.

Check the exhibition packages.

You want to discover who you will meet in the exhibition area?

Check the full exhibitors’ list.

You have a technology to promote?

BioFIT and the SATT network (the association of the French TTOs), jointed their initiatives to launch the Technomarket & Presenting Technologies session during BioFIT 2015.

The presenting technologies aims at matching the needs of academia, TTO and academia spin-off seeking alliances and business development opportunities on innovative projects.

 

If your innovative product, technology, knowhow or research result is related to :

• devices / imaging
• cardio metabolic diseases
• immunology / oncology
• infectious diseases / vaccines

apply for the Technomarket & Presenting Technologies sessions and have the chance to present it during BioFIT !

For more information, contact us!

How can Open-Innovation be a powerful driver for One Health dynamics?

 

As diverse as they are complementary, our panelists will address the common challenges faced by human and animal health and highlight the benefits and limits of open-innovation collaborations across this sectors.

The solutions to these common challenges may be provided by the One Health dynamics and be powerful drivers for tomorrow’s innovations. Cross sector collaborations could lead to a faster development of health tools and technologies that will both protect against infectious diseases while helping tackle some of the major chronic disease challenges of the 21^st century.

 

To address this exciting cross-sector session :

• Pineau Thierry (moderator) INRA Animal Health Metaprogram Director, INRA UNIVERSITY, FRANCE
• Arnouts Sven, Business development Manager , PROVAXS, BELGIUM
• Dubruque Matthieu, COO, Oncovet Clinical Research, France
• Hanon Emmanuel, Senior Vice President, GSK VACCINES, UK
• Dieuzy-Labaye Isabelle, Director, Strategic Alliances, ZOETIS, FRANCE

 

 

Scheduled December 1st at 2pm, we are already looking forward to listening to these heavy league speakers !

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us!

IDEA Summit, European event dedicated to translational research on diabetes is organized by Eurasanté, NHL cluster & Lund University and will be hosted by BioFIT. You want to learn more about IDEA Summit & BioFIT 2015?

We will attend EASD 51st Annual Meeting 2015

On Wednesday 2^nd, in Strasbourg’s PMC, will be addressed within BioFIT, the hot topic of Crowd-funding’s place in Drug Development. 

Chaired by Cormac Sheridan, journalist at BioWorld today, Ireland, this session will confront the opinions of Mohammed Charki, Research and Development Partnerships Director of Sanofi, Ajan Reginald, Chief Executive of Cell Therapy, Daniel Olivier, CEO of Capital Cell, and Fabrice Beauchêne, CEO of My Pharma Company

Does it have a place or does it not ? This session is digging for more than a simple yes/no answer, chairman Cormac Sheridan described the session in these terms :

“To many of us, drug development is just about the last field one would associate with crowdfunding. Although it has become a useful adjunct to traditional methods of raising money for cultural and philanthropic initiatives and even for for-profit tech ventures, crowdfunding does not seem to fit the more formal fundraising culture of biotechnology. The capital requirements and the long-term investment horizons of drug development both militate against the buzzy ‘viral’ culture of crowdfunding. And yet, as a recent report from the Berlin-based research consultancy Biocom AG confirms, a growing number of European life sciences firms, particularly in France and the UK, has started to explore its possibilities. Biocom identified 42 campaigns (in biotech and medtech), which raised a combined €23 million over the past five years. Ten firms raised €1 million or more. Crowdfunding platforms with a specialist focus on life sciences have now started to emerge, and some are introducing new investment models. Does this represent a passing fad? Or the beginning of something big? How will stock exchanges (the ultimate crowdfunding platforms) engage with crowdfunding platforms? Which biotech companies should engage with them? And how? Join us to explore the potential for crowdfunding in drug development.”

What do you think ? Is there a place for crowd-funding in drug development ? Come share your opinion with our panel, we are already looking forward to attending this hot debate !

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us